[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Roivant Sciences Ltd (ROIV)

Roivant Sciences Ltd (ROIV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Roivant's Pipeline Transparency Test Arrives as Brepocitinib Nears Its First Commercial Moment

Roivant Sciences Ltd (ROIV) is scheduled to report fiscal first quarter 2027 earnings on August 6, 2026, before market open. With the stock trading at $34.60 and analysts expecting a loss of $-0.45 per share, investors face a critical question: can the biopharmaceutical company's promising pipeline developments offset widening losses and justify the recent 30% rally from its 200-day moving average? The report comes at a pivotal moment as management anticipates multiple catalysts in 2026, including Phase 3 readouts for key drug candidates brepocitinib and mosliciguat.

Roivant Sciences is a biopharmaceutical company focused on developing and commercializing medicines for orphan diseases through its portfolio of subsidiary companies...

Fundamentals

See More
  • Market Capitalization, $K 24,886,742
  • Shares Outstanding, K 719,270
  • Annual Sales, $ 8,260 K
  • Annual Income, $ -299,770 K
  • EBIT $ -1,285 M
  • EBITDA $ -1,282 M
  • 60-Month Beta 1.12
  • Price/Sales 3,012.05
  • Price/Cash Flow N/A
  • Price/Book 4.71

Options Overview Details

View History
  • Implied Volatility 52.20% (-6.71%)
  • Historical Volatility 32.43%
  • IV Percentile 60%
  • IV Rank 36.52%
  • IV High 87.70% on 02/11/26
  • IV Low 31.79% on 10/03/25
  • Expected Move (DTE 15) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.47
  • Today's Volume 959
  • Volume Avg (30-Day) 201
  • Put/Call OI Ratio 0.39
  • Today's Open Interest 46,630
  • Open Int (30-Day) 47,752
  • Expected Range 35.11 to 35.11

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.45
  • Number of Estimates 1
  • High Estimate $-0.45
  • Low Estimate $-0.45
  • Prior Year $-0.30
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.47 +8.16%
on 08/03/26
37.00 -5.08%
on 07/10/26
-0.27 (-0.76%)
since 07/06/26
3-Month
27.85 +26.10%
on 05/19/26
37.00 -5.08%
on 07/10/26
+6.30 (+21.86%)
since 05/06/26
52-Week
10.90 +222.20%
on 08/11/25
37.00 -5.08%
on 07/10/26
+23.47 (+201.46%)
since 08/06/25

Most Recent Stories

More News
Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)

CS is a highly morbid, chronic, and disfiguring condition with no approved therapies Brepocitinib is the first investigational therapy to generate a positive result in a placebo-controlled CS study (Phase...

ROIVW : 2.75 (-3.85%)
ROIV : 35.11 (+1.47%)
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat...

IMVT : 39.74 (+1.17%)
ROIV : 35.11 (+1.47%)
Roivant Reports Financial Results for the First Quarter Ended June 30, 2026, and Provides Business Update

Commercial preparations for brepocitinib in dermatomyositis (DM) are progressing well and on track for launch by the end of September 2026; topline data from Phase 3 study in non-infectious uveitis (NIU)...

ROIVW : 2.75 (-3.85%)
ROIV : 35.11 (+1.47%)
Roivant's Pipeline Transparency Test Arrives as Brepocitinib Nears Its First Commercial Moment

Barchart Research What to Expect from ROIV Earnings ROIV Generated August 5, 2026 Current Price $34.60 EPS Estimate $$-0.45 Consensus Rating Strong Buy Average Move 7.24% Roivant's Pipeline Transparency...

ROIV : 35.11 (+1.47%)
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

DURHAM, N.C., July 23, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq:  IMVT ) today announced that it will report its financial results for the first quarter ended June 30, 2026 on Thursday, August...

IMVT : 39.74 (+1.17%)
ROIV : 35.11 (+1.47%)
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026

BASEL, Switzerland and LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday,...

ROIVW : 2.75 (-3.85%)
ROIV : 35.11 (+1.47%)
Roivant Sciences Q4 Earnings Call Highlights

Roivant Sciences (NASDAQ:ROIV) executives used the company’s fourth-quarter earnings call to highlight new open-label data for IMVT-1402 in difficult-to-treat rheumatoid arthritis, upcoming pulmonary...

ROIV : 35.11 (+1.47%)
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant...

ROIVW : 2.75 (-3.85%)
ROIV : 35.11 (+1.47%)
Roivant's Cash Runway Gets Its Clearest Disclosure in a Year

Barchart Research What to Expect from ROIV Earnings ROIV Generated May 19, 2026 Current Price $28.20 EPS Estimate $$-0.38 Consensus Rating Strong Buy Average Move 5.78% Roivant's Cash Runway Gets Its Clearest...

ROIV : 35.11 (+1.47%)
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026 

DURHAM, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq:  IMVT ) today announced that it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026,...

IMVT : 39.74 (+1.17%)
ROIV : 35.11 (+1.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 36.53
2nd Resistance Point 36.05
1st Resistance Point 35.32
Last Price 35.11
1st Support Level 34.11
2nd Support Level 33.63
3rd Support Level 32.90

See More

52-Week High 37.00
Last Price 35.11
Fibonacci 61.8% 27.03
Fibonacci 50% 23.95
Fibonacci 38.2% 20.87
52-Week Low 10.90

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.